Aravive Investor Presentation Deck

Promising Responses in Patients in Later Lines of Therapy and < 3 Month Platinum-Free Interval Compared to Literature Invasive Tumors Resistant to Multiple Lines of Therapy Expected to Be Dependent on the GAS6/AXL Pathway CLINICAL RESPONSE OF BATIRAXCEPT+ CHEMO IN PATIENTS WITH < 3MO PLATINUM FREE INTERVAL (N=12) CLINICAL RESPONSE OF BATIRAXCEPT+ CHEMO' IN 3rd LINE & 4th LINE (N=20) 80% 70% 50% 40% 30% 20% 10% 0% 80% 70% 60% 50% 40% 30% 20% 10% 0% ORR ORR SD SD CBR CBR PD PD CLINICAL RESPONSE OF CHEMOTHERAPY IN 90% PATIENTS WITH < 3MO 80% 70% PLATINUM FREE INTERVAL (N=21) CLINICAL RESPONSE OF CHEMOTHERAPY IN 3rd LINE AND 4th LINE (N=99) 60% 50% 40% 30% 20% 10% 90% 80% 70% 60% 50% 40% 30% 20% 10% ORR ORR SD SD "Als and both chemo cohorical at Cancer Chemotherapy and Pharmalogy (2013) 14:33-39 17: noved PLD GEM: CPT-11 (notecanoporeananda Gynecology and Reproductivelogy 180 (2013) 14-8 ned in order of us al carboplatin, apotean, etoposide, Demar, cox tamoxifen, Aranyon, sabotax and other predmety CBR CBR PD PD Rainha(Ponal data 18

View entire presentation